Kyverna Therapeutics Statistics
Total Valuation
KYTX has a market cap or net worth of $90.76 million. The enterprise value is -$186.98 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KYTX has 43.22 million shares outstanding. The number of shares has increased by 6,211.07% in one year.
| Current Share Class | 43.22M |
| Shares Outstanding | 43.22M |
| Shares Change (YoY) | +6,211.07% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 12.73% |
| Owned by Institutions (%) | 39.25% |
| Float | 17.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.61 |
| Quick Ratio | 8.47 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,004.25 |
Financial Efficiency
Return on equity (ROE) is -80.74% and return on invested capital (ROIC) is -53.52%.
| Return on Equity (ROE) | -80.74% |
| Return on Assets (ROA) | -46.93% |
| Return on Invested Capital (ROIC) | -53.52% |
| Return on Capital Employed (ROCE) | -52.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.14M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.14% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -88.14% |
| 50-Day Moving Average | 2.38 |
| 200-Day Moving Average | 4.84 |
| Relative Strength Index (RSI) | 47.94 |
| Average Volume (20 Days) | 291,538 |
Short Selling Information
The latest short interest is 2.95 million, so 6.82% of the outstanding shares have been sold short.
| Short Interest | 2.95M |
| Short Previous Month | 2.87M |
| Short % of Shares Out | 6.82% |
| Short % of Float | 16.44% |
| Short Ratio (days to cover) | 9.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | -112.47M |
| Operating Income | -142.60M |
| Pretax Income | n/a |
| Net Income | -127.48M |
| EBITDA | -141.42M |
| EBIT | -142.60M |
| Earnings Per Share (EPS) | -$3.33 |
Full Income StatementBalance Sheet
The company has $285.98 million in cash and $8.24 million in debt, giving a net cash position of $277.74 million or $6.43 per share.
| Cash & Cash Equivalents | 285.98M |
| Total Debt | 8.24M |
| Net Cash | 277.74M |
| Net Cash Per Share | $6.43 |
| Equity (Book Value) | 266.59M |
| Book Value Per Share | 6.17 |
| Working Capital | 256.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$114.25 million and capital expenditures -$2.21 million, giving a free cash flow of -$116.46 million.
| Operating Cash Flow | -114.25M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -116.46M |
| FCF Per Share | -$2.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |